Gadolinium as a neutron capture therapy agent

The clinical results of treating brain tumors with boron neutron capture therapy are very encouraging. Researchers around the world are once again making efforts to develop this therapeutic modality. Gadolinium‐157 is one of the nuclides that holds interesting properties of being a neutron capture therapy agent. It is estimated that tumor concentrations of up to 300 μg 157 Gd/g tumor can be achieved in brain tumors with some MRI contrast agents such as Gd‐DTPA and Gd‐DOTA, and up to 800 μg 157 Gd/g tumor can be established in bone tumors with Gd‐EDTMP. Monte Carlo calculations indicate that with 250 ppm of 157 Gd in tumor, neutron capture therapy can deliver 2000 cGy to a tumor of 2‐cm diameter or larger with 5×10 12 n/cm 2 of thermal neutron fluence at the tumor. Dose measurements with films and TLDs in phantoms verified these calculations. More extended Monte Carlo calculations demonstrate that neutron capture therapy with Gd possesses comparable dose distribution to B neutron capture therapy. With 5×10 12 n/cm 2 thermal neutrons at the tumor, Auger electrons from the Gd produced an optical density enhancement on films that is similar to the effect caused by about 300 cGy of Gd prompt gamma dose and may further enhance the therapeutic effects.